Advertisement

Standards for the Socioeconomic Evaluation of Health Care Services

  • Bryan R. Luce
  • Anne Elixhauser
  • A. J. Culyer

Part of the Health Systems Research book series (HEALTH)

Table of contents

  1. Front Matter
    Pages I-XV
  2. Socioeconomic Evaluations: an Executive Summary

    1. A. J. Culyer, B. Luce, A. Elixhauser
      Pages 1-12
  3. Guidelines for the Evaluator

    1. Front Matter
      Pages 13-13
    2. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 15-20
    3. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 21-29
    4. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 30-43
    5. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 44-55
    6. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 56-67
    7. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 68-76
    8. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 77-82
    9. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 83-93
    10. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 94-105
  4. Technical Aspects

    1. Front Matter
      Pages 107-107
    2. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 109-116
    3. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 117-123
    4. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 124-126
    5. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 127-133
    6. Bryan R. Luce, Anne Elixhauser, A. J. Culyer
      Pages 134-143
  5. Back Matter
    Pages 144-184

About this book

Introduction

Over the past decades, health care delivery - once characterized by clearly defined relationships between medical professionals, regulators, and industr- has become much more complex. Traditional roles and relationships are changing and new decision-makers are entering the scene. They bring into the discussion the need for cost containment and the changing perceptions of the public with regard to the risks and benefits of health care outcomes. As benefits of medical care are increasingly questioned and as scepticism and fear of advanced technologies are demonstrated by a growing body of people, decision making must move beyond medical concerns to encompass economic, political, and sociological considera­ tions. This evolution has also affected the pharmaceutical industry. Public percep­ tion of responsibility for product safety is no longer limited to regulators and physi­ cians. Manufacturers, previously unencumbered by social policies, governmental preoccupations, or public expectations, are now held accountable for product safety. As a certain amount of risk acceptance is, however, a prerequisite for the further development of health care goods, it has to be carefully balanced against society'S demand for safety. To weigh risks against benefits, to define acceptable risk, and to exclude what no longer falls within this category remain perpetual challenges. Accordingly, health care outcomes have to be assessed not only from a clinical point of view, but also from an economic and societal perspective. The assessment of drug risks and benefits has become an important political issue world-wide.

Keywords

Kosten-Effektivitäts-Analyse Kosten-Nutzen-Analyse analysis of variance assessment care correlation health health care organizations quality of life statistics

Authors and affiliations

  • Bryan R. Luce
    • 1
  • Anne Elixhauser
    • 1
  1. 1.Medical Technology and Policy Research CenterBattelleUSA

Editors and affiliations

  • A. J. Culyer
    • 1
  1. 1.Department of Economics and Related StudiesUniversity of YorkHeslington, YorkEngland

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-75490-6
  • Copyright Information Springer-Verlag Berlin Heidelberg 1990
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-75492-0
  • Online ISBN 978-3-642-75490-6
  • Series Print ISSN 1431-4002
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology